SCHEMBL7035440

SCHEMBL7035440

CCn1c(=O)c2cc(C(=O)O)sc2n(C)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.40
ALDH1A1 P00352 8/20 0.40
HPGD P15428 3/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
GFER P55789 1/20 0.39
HSD17B10 Q99714 3/20 0.39
PKM P14618 1/20 0.39
STAT1 P42224 1/20 0.39
SRC P12931 1/20 0.38
TP53 P04637 3/20 0.38
THRB P10828 1/20 0.38
PDE4A P27815 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7021108 0.90 ALDH1A1 (0.41) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL7020488 0.84 TRPA1 (0.41) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL6254110 0.83 TRPA1 (0.48) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL6729378 0.82 ALDH1A1 (0.55) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL7105492 0.82 HDAC8 (0.47) KDM4EALDH1A1KMT2AMAPTTP53
SCHEMBL6254904 0.80 MAPK8 (0.41) ALDH1A1
SCHEMBL7105942 0.80 ADORA2B (0.48) KDM4EALDH1A1KMT2AMAPTTP53
SCHEMBL7038890 0.80 MMP13 (0.46) KDM4ESMN1; SMN2MAPT
SCHEMBL6253141 0.80 MMP13 (0.45) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL6703224 0.78 PTGS1 (0.41) PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 KDM4E 1577/4885ALDH1A1 812/4885HPGD 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.